Microsoft Word - Decitabine Figure 1.doc - Azacitidine - Document - PDFSEARCH.IO - Document Search Engine

<--- Back to Details

First Page		Document Content
Triazines Myelodysplastic syndrome Syndromes Azacitidine Decitabine Hypomethylating agent Acute myeloid leukemia DNA methyltransferase Lenalidomide Medicine Oncology Nucleosides		Microsoft Word - Decitabine Figure 1.doc Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 235,84 KB Share Document on Facebook

Similar Documents

	July 8, 2013 Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator Investigational New Drug (IND) Application and Data Presentations Planned for the Fourth Quarter DUBLIN, DocID: 11nTT - View Document
$Comparison of the Efficacy and Safety of 5-day and 10day schedules of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory Acute Myeloid Leukemia (r/r AML) Gail J. Roboz$	Comparison of the Efficacy and Safety of 5-day and 10day schedules of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory Acute Myeloid Leukemia (r/r AML) Gail J. Roboz DocID: 10hcE - View Document
	Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA) DocID: 10gfI - View Document
	SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters the methylation signature of HCC cell lines No[removed]Simone Jueliger1, John Lyons1, Mohammad Azab2 and Pietro Taverna2 DocID: Z4RY - View Document
$DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML$	DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML DocID: Z1WQ - View Document